Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Adult Solid Tumor|Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum|Adult Central Nervous System Germ Cell Tumor|Adult Teratoma|Benign Teratoma|Estrogen Receptor-negative Breast Cancer|Estrogen Receptor-positive Breast Cancer|Familial Testicular Germ Cell Tumor|HER2-negative Breast Cancer|HER2-positive Breast Cancer|Male Breast Cancer|Ovarian Immature Teratoma|Ovarian Mature Teratoma|Ovarian Monodermal and Highly Specialized Teratoma|Progesterone Receptor-negative Breast Cancer|Progesterone Receptor-positive Breast Cancer|Recurrent Breast Cancer|Recurrent Colon Cancer|Recurrent Extragonadal Germ Cell Tumor|Recurrent Extragonadal Non-seminomatous Germ Cell Tumor|Recurrent Extragonadal Seminoma|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Melanoma|Recurrent Ovarian Germ Cell Tumor|Recurrent Rectal Cancer|Stage III Extragonadal Non-seminomatous Germ Cell Tumor|Stage III Extragonadal Seminoma|Stage III Malignant Testicular Germ Cell Tumor|Stage III Ovarian Germ Cell Tumor|Stage IV Breast Cancer|Stage IV Colon Cancer|Stage IV Extragonadal Non-seminomatous Germ Cell Tumor|Stage IV Extragonadal Seminoma|Stage IV Melanoma|Stage IV Ovarian Germ Cell Tumor|Stage IV Rectal Cancer|Testicular Immature Teratoma|Testicular Mature Teratoma
Interventions: DRUG: PD-0332991
Sponsor: Abramson Cancer Center at Penn Medicine